Do analysts prefer ANEB or INKT?

MiNK Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 217.81%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MiNK Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has better earnings and valuation, ANEB or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A

Is ANEB or INKT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% MiNK Therapeutics N/A N/A -118.57%

Do analysts recommend DWTX or ANEB?

Dogwood Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 541.37%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, DWTX or ANEB?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is DWTX or ANEB more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts recommend TCRX or ANEB?

TScan Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 703.21%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe TScan Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CTOR or ANEB?

Citius Oncology currently has a consensus price target of $6.00, suggesting a potential upside of 809.09%. Given Citius Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Citius Oncology is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CTOR or ANEB?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is CTOR or ANEB more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts rate INCR or ANEB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anebulo Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is INCR or ANEB more profitable?

InterCure's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Anebulo Pharmaceuticals N/A -74.57% -68.96%

Anebulo Pharmaceuticals (ANEB) Competitors

$0.32 0.00 (0.00%)

As of 08/3/2026 10:01 AM Eastern

Compare

ANEB vs. INKT, DWTX, TCRX, CTOR, and INCR

Should you buy Anebulo Pharmaceuticals stock or one of its competitors? MarketBeat compares Anebulo Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anebulo Pharmaceuticals include MiNK Therapeutics (INKT), Dogwood Therapeutics (DWTX), TScan Therapeutics (TCRX), Citius Oncology (CTOR), and InterCure (INCR).

How does Anebulo Pharmaceuticals compare to MiNK Therapeutics?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MiNK Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 217.81%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

MiNK Therapeutics' return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
MiNK Therapeutics	N/A	N/A	-118.57%

In the previous week, Anebulo Pharmaceuticals' average media sentiment score of 0.00 equaled MiNK Therapeutics'average media sentiment score.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
MiNK Therapeutics	Neutral

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

Anebulo Pharmaceuticals has a beta of -1.83, suggesting that its stock price is 283% less volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

Summary

Anebulo Pharmaceuticals and MiNK Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Dogwood Therapeutics has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.83, indicating that its share price is 283% less volatile than the broader market.

Dogwood Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 541.37%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 0 mentions for Anebulo Pharmaceuticals. Dogwood Therapeutics' average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Dogwood Therapeutics	Neutral
Anebulo Pharmaceuticals	Neutral

Anebulo Pharmaceuticals' return on equity of -74.57% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Summary

Dogwood Therapeutics beats Anebulo Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

TScan Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 703.21%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe TScan Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anebulo Pharmaceuticals has lower revenue, but higher earnings than TScan Therapeutics. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	4.73	-$129.77M	-$0.96	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

In the previous week, TScan Therapeutics had 2 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for TScan Therapeutics and 0 mentions for Anebulo Pharmaceuticals. TScan Therapeutics' average media sentiment score of 0.97 beat Anebulo Pharmaceuticals' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Positive
Anebulo Pharmaceuticals	Neutral

Anebulo Pharmaceuticals has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Anebulo Pharmaceuticals' return on equity of -74.57% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

TScan Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.83, indicating that its share price is 283% less volatile than the broader market.

Summary

TScan Therapeutics beats Anebulo Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Citius Oncology has a beta of 3.48, suggesting that its stock price is 248% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.83, suggesting that its stock price is 283% less volatile than the broader market.

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Citius Oncology's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Citius Oncology	Neutral
Anebulo Pharmaceuticals	Neutral

Anebulo Pharmaceuticals' return on equity of -74.57% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Citius Oncology currently has a consensus price target of $6.00, suggesting a potential upside of 809.09%. Given Citius Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Citius Oncology is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Summary

Citius Oncology beats Anebulo Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to InterCure?

InterCure (NASDAQ:INCR) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

InterCure's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

InterCure has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.83, suggesting that its share price is 283% less volatile than the broader market.

8.3% of InterCure shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anebulo Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anebulo Pharmaceuticals has lower revenue, but higher earnings than InterCure. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.67	-$10.37M	$0.03	31.93
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

In the previous week, InterCure's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
InterCure	Neutral
Anebulo Pharmaceuticals	Neutral

Summary

InterCure beats Anebulo Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Anebulo Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANEB vs. The Competition

Export

Metric	Anebulo Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.05M	$3.54B	$6.80B	$13.01B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-1.68	7.36	279.98	25.51
Price / Sales	N/A	1,272.68	649.35	116.02
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	1.14	17.18	11.15	6.35
Net Income	-$8.48M	-$12.52M	$3.48B	$347.60M
7 Day Performance	-3.03%	2.48%	2.51%	3.14%
1 Month Performance	-15.79%	-5.41%	-2.78%	-2.08%
1 Year Performance	-88.15%	51.14%	64.32%	21.27%

Anebulo Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANEB Anebulo Pharmaceuticals	N/A	$0.32 flat	N/A	-88.8%	$13.05M	N/A	N/A	4
INKT MiNK Therapeutics	2.541 of 5 stars	$10.38 -1.5%	$35.00 +237.2%	-27.4%	$52.51M	N/A	N/A	30
DWTX Dogwood Therapeutics	2.5339 of 5 stars	$1.54 -0.6%	$12.00 +679.2%	-64.7%	$52.13M	N/A	N/A	5	News Coverage
TCRX TScan Therapeutics	3.2676 of 5 stars	$0.74 -4.2%	$6.00 +709.1%	-55.3%	$50.58M	$10.32M	N/A	100	Upcoming Earnings
CTOR Citius Oncology	2.1151 of 5 stars	$0.54 -0.9%	$6.00 +1,018.8%	-69.6%	$50.34M	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANEB) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. INKT, DWTX, TCRX, CTOR, and INCR

How does Anebulo Pharmaceuticals compare to MiNK Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to Dogwood Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to TScan Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to Citius Oncology?

Summary

How does Anebulo Pharmaceuticals compare to InterCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. INKT, DWTX, TCRX, CTOR, and INCR

How does Anebulo Pharmaceuticals compare to MiNK Therapeutics?

Do institutionals and insiders hold more shares of ANEB or INKT?

Do analysts prefer ANEB or INKT?

Is ANEB or INKT more profitable?

Does the media refer more to ANEB or INKT?

Which has better earnings and valuation, ANEB or INKT?

Which has more volatility & risk, ANEB or INKT?

Summary

How does Anebulo Pharmaceuticals compare to Dogwood Therapeutics?

Which has more risk and volatility, DWTX or ANEB?

Do analysts recommend DWTX or ANEB?

Do insiders & institutionals have more ownership in DWTX or ANEB?

Does the media favor DWTX or ANEB?

Is DWTX or ANEB more profitable?

Which has better valuation & earnings, DWTX or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to TScan Therapeutics?

Do insiders and institutionals have more ownership in TCRX or ANEB?

Do analysts recommend TCRX or ANEB?

Which has higher earnings and valuation, TCRX or ANEB?

Does the media favor TCRX or ANEB?

Is TCRX or ANEB more profitable?

Which has more volatility and risk, TCRX or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to Citius Oncology?

Which has more volatility & risk, CTOR or ANEB?

Do insiders & institutionals hold more shares of CTOR or ANEB?

Does the media favor CTOR or ANEB?

Is CTOR or ANEB more profitable?

Do analysts prefer CTOR or ANEB?

Which has stronger earnings and valuation, CTOR or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to InterCure?

Is INCR or ANEB more profitable?

Which has more risk & volatility, INCR or ANEB?

Do institutionals and insiders have more ownership in INCR or ANEB?

Do analysts rate INCR or ANEB?

Which has stronger earnings and valuation, INCR or ANEB?

Does the media favor INCR or ANEB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools